BCL-2 inhibitorPhase 3 trialInvestigational
Venetoclax
How it works
Blocks the BCL-2 protein, which helps cancer cells survive, allowing the immune system to destroy them.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 80% of patients achieved a complete or partial response, with a median progression-free survival of approximately 14 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Trial for Acute Myeloid Leukemia Treatment in India | Leukemia | preclinical | — | Source → |
| Understanding Resistance to Venetoclax in Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| Testing a Combination of Medications for Relapsed/Refractory T-cell Prolymphocytic Leukemia | Leukemia | phase-1 | — | Source → |
| Trial to Improve Treatment for Children with T-Cell Leukemia or Lymphoma | Leukemia | phase-2 | — | Source → |
| Testing Different Treatment Lengths for Venetoclax in Older Adults with Newly Diagnosed Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Treatments for High-Risk Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Adult Acute Lymphoblastic Leukemia Treatment Trial | Leukemia | preclinical | — | Source → |
| New Treatment Combination Tested for Older AML Patients | Leukemia | phase-3 | Median overall survival was 8.2 months with ATRA versus 5.1 months without ATRA. | Source → |
| Testing Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients | Leukemia | preclinical | — | Source → |
| Combination Therapy for Untreated Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Venetoclax Concentrations Linked to Risk of Febrile Neutropenia in Acute Leukemia | Leukemia | observational | — | Source → |
| Combination Therapy for Acute Myeloid Leukemia: A Phase 2 Clinical Trial | Leukemia | phase-2 | — | Source → |
| Testing Cladribine and Venetoclax for Monocytic Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Studying Genetic Factors in Acute Myeloid Leukemia | Leukemia | preclinical | — | Source → |
| Testing Venetoclax and ASTX727 for High-Risk Blood Disorders | Leukemia | phase-1 | — | Source → |
| Testing Venetoclax and Vincristine in Relapsed Leukemia Patients | Leukemia | phase-1 | — | Source → |
| Studying CLL Treatment with Venetoclax | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma | Leukemia | phase-1 | — | Source → |
| Study of Venetoclax in Chronic Lymphocytic Leukemia | Leukemia | preclinical | — | Source → |
| Testing a New Approach to Monitor CLL and SLL with Next-Generation Sequencing | Leukemia | phase-2 | — | Source → |
| Combining Venetoclax and Obinutuzumab to Treat Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing a New Treatment for Relapsed CLL | Leukemia | phase-2 | — | Source → |
| Testing Olutasidenib with Azacitidine for Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Olutasidenib in Patients with Relapsed AML and IDH1 Mutation | Leukemia | phase-2 | — | Source → |
| Combining Venetoclax and Azacitidine for Acute Myeloid Leukemia Treatment | Leukemia | phase-2 | — | Source → |
| Eltanexor and Venetoclax for Relapsed or Refractory Blood Cancers | Leukemia | phase-1 | — | Source → |
| Testing DZD8586 in Combination with Venetoclax for CLL/SLL | Leukemia | phase-2 | — | Source → |
| Testing 8-Chloroadenosine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing a New Combination Therapy for Pediatric Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Venetoclax-based Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia | Leukemia | preclinical | — | Source → |
| New Study Compares Treatment Options for Acute Myeloid Leukemia | Leukemia | phase-3 | The overall response rate in the VEN/HMA cohort was higher than in the LIC or IC cohort (72.7% vs. 42.1%, p = 0.010; 72.7% vs. 54.3%, p = 0.049). | Source → |
| Testing New Treatments for a Specific Type of Leukemia | Leukemia | phase-2 | — | Source → |
| Study of Decitabine, Venetoclax, and Ponatinib for Leukemia Treatment | Leukemia | phase-2 | — | Source → |
| Study of Ibrutinib and Venetoclax for Chronic Lymphocytic Leukemia | Leukemia | preclinical | — | Source → |
| Testing Acalabrutinib and Venetoclax for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Leukemia | phase-2 | — | Source → |
| Testing a New Treatment Combination for Higher-Risk Myelodysplastic Syndromes | Leukemia | phase-1 | — | Source → |
| Testing a Combination Treatment for Relapsed or Refractory Acute Myeloid Leukemia in Children | Leukemia | phase-1 | — | Source → |
| Testing Q702 with Azacitidine and Venetoclax for Leukemia | Leukemia | phase-1 | — | Source → |
| Testing a New Treatment Combination for Acute Myelogenous Leukemia | Leukemia | phase-2 | — | Source → |
| Study of Nemtabrutinib and Venetoclax in CLL/SLL Patients | Leukemia | phase-3 | — | Source → |
| Comparing Treatments for Newly Diagnosed AML Patients | Leukemia | phase-2 | — | Source → |
| Acute Myeloblastic Leukemia Study Examines Venetoclax | Leukemia | preclinical | — | Source → |
| New Treatment Combination for Newly Diagnosed Acute Myeloid Leukemia | Leukemia | phase-3 | — | Source → |
| Testing Venetoclax and Azacitidine for Untreated AML Patients | Leukemia | phase-2 | — | Source → |
| Comparing Treatments for Newly Diagnosed Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Testing Decitabine and Venetoclax as Maintenance Therapy After Stem Cell Transplant | Leukemia | phase-1 | — | Source → |
| Testing Navitoclax, Venetoclax, and Decitabine for Relapsed or Refractory Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| New Trial Investigates Treatment for Newly Diagnosed AML or MDS-EB-2 | Leukemia | phase-3 | — | Source → |
| New Treatment Combination for Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Evaluating Treatments for Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Leukemia | phase-3 | — | Source → |
| Testing Venetoclax with CLAG-M for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Combination Therapy for Relapsed or Refractory Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Leukemia | phase-2 | — | Source → |
| Testing Venetoclax with CACAG Regimen for Acute Monocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Zanubrutinib, Obinutuzumab, and Venetoclax for CLL or SLL | Leukemia | phase-2 | — | Source → |
| Continuing Study of Venetoclax for Various Blood Cancers | Leukemia | phase-3 | — | Source → |
| Study of CLL Treatment Combination | Leukemia | phase-3 | — | Source → |
| Testing a Combination of Anti-Cancer Drugs for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing a New Treatment for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing a New Chemotherapy Drug Combination in Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Venetoclax and HMA Treatment for Older Adults with FLT3 Mutated AML | Leukemia | phase-2 | — | Source → |
| Customizing Ibrutinib Treatment for Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Dasatinib Monotherapy for Acute Myeloid Leukemia Patients | Leukemia | phase-2 | — | Source → |
| New Treatment Combination for Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Leukemia | phase-2 | — | Source → |
| Testing a New Combination Therapy for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Outcomes after Menin Inhibitors Fail in Leukemia Patients | Leukemia | observational | The complete response (CR)/CR with incomplete hematologic recovery (CRi) rate for nontrial therapies was 19% (n = 7); overall response rate was 32% (n = 12). | Source → |
| Testing Venetoclax and ASTX727 for Leukemia and Blood Disorders | Leukemia | phase-2 | — | Source → |
| New Combination Therapy for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Venetoclax in High-Risk Blood Cancers | Leukemia | phase-1 | — | Source → |
| Testing Ivosidenib and Venetoclax for IDH1 Mutated Hematologic Malignancies | Leukemia | phase-1 | — | Source → |
| New Cancer Treatment Combination Shows Promise Against Leukemia | Leukemia | lab-study | The triple CAV combination exerted a far stronger inhibitory effect than any single agent or dual-drug combination (p < 0.01) and showed synergistic interactions (combination index <1). | Source → |
| Testing Venetoclax for Relapsed Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Testing New Treatments for Young Adults with Intermediate Risk Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Combination Therapy Improves Outcomes in Certain Leukemia Patients | Leukemia | meta-analysis | The DEC + VEN cohort had a lower early mortality rate than the DEC cohort (30-day mortality: 2.7%-5% vs. 9.7%, p = 0.01; RR = 0.90, 95% CI 0.83-0.97 versus RR = 0.97, 95% CI 0.92-1.02). | Source → |
| Venetoclax levels linked to AML treatment outcomes | Leukemia | lab-study | Patients with trough levels below 1857.3 ng/mL had lower rates of hematologic toxicity during the first treatment cycle (92.9% vs. 100%, P = 0.041). | Source → |
| Targeted Delivery of Cancer Drug in Leukemia Cells | Leukemia | lab-study | — | Source → |
| Combining Venetoclax with HEA Regimen Shows Promise for AML Patients | Leukemia | phase-2 | The total CR rate of VHEA regimen in 6 patients with gene rearrangement AML was 83.3% (5/6). | Source → |
| New Therapy for Leukemia Relapse | Leukemia | observational | — | Source → |
| Long-term remission with combination therapy in AML patient | Leukemia | observational | — | Source → |
| Monitoring Drug Levels in Leukemia Patients | Leukemia | lab-study | — | Source → |
| BCL2 Proteins May Predict Resistance to Leukemia Treatment | Leukemia | lab-study | — | Source → |
| Tiny particles help leukemia treatment work better | Leukemia | lab-study | — | Source → |
| Venetoclax Exposure Linked to Better Outcomes in Chinese Pediatric Leukemia Patients | Leukemia | observational | Exposure-response analyses demonstrated a consistent positive association between higher VEN exposure and MRD negativity. | Source → |
| New Cancer Treatment Regimens Compared for Acute Myeloid Leukemia | Leukemia | phase-3 | — | Source → |
| Combination Therapies for Acute Myeloid Leukemia | Leukemia | review | — | Source → |
| Venetoclax Efficacy and Safety in Real-World AML Patients | Leukemia | observational | Median overall survival for the entire cohort was 17.8 months, with 1- and 2-year survival rates of 51% and 36.4%, respectively. | Source → |
| Combining Two Drugs May Help Treat Leukemia | Leukemia | lab-study | — | Source → |
| New Compound May Improve Leukemia Treatment | Leukemia | lab-study | — | Source → |
| Venetoclax and Obinutuzumab Combination Shows Promise in Untreated Japanese CLL and SLL Patients | Leukemia | phase-2 | The IRC-assessed CR/CRi rate based on the best overall response was 90.0% (95% confidence interval 55.5%, 99.7%). | Source → |
| Real-world outcomes of venetoclax and azacitidine in Japanese patients with AML | Leukemia | observational | The rate of complete remission (CR) or CR with incomplete blood count recovery was 56.7% in VEN + AZA-treated patients. | Source → |
| Plant Compounds May Help Overcome Leukemia Resistance | Leukemia | review | — | Source → |
| Combination Therapy Shows Promise in Treating Leukaemia | Leukemia | phase-1/2 | The overall response rate was 62% (95% CI 41-80; 16 of 26) in patients with AML. | Source → |
| Venetoclax Plus Low-Intensity Therapy May Help Some AML Patients | Leukemia | phase-3 | The overall remission rate was 78.7% vs. 60.0%, and complete remission rate was 48.0% vs. 21.3%. | Source → |
| Researchers Create Resistant Leukemia Cells to Study Treatment | Leukemia | lab-study | — | Source → |
| Venetoclax Combination Therapy for Leukemia | Leukemia | phase-2 | — | Source → |
| New Treatment Approach for Young Adults with Leukaemia | Leukemia | observational | — | Source → |
| New Study Compares Effectiveness of Two Leukemia Treatments | Leukemia | phase-3 | Treatment with OLU versus IVO was associated with significantly higher rates of complete response (RD: 0.25; 95%CI: 0.01, 0.49), transfusion independence (RD: 0.27; 95%CI: 0.01, 0.53), and OS (HR: 0.33; 95%CI: 0.11, 0.94). | Source → |
| Researchers Map How Leukemia Cells Evade Treatment | Leukemia | lab-study | — | Source → |
| Venetoclax Sensitivity and Resistance in Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| New Treatment Option for Cancer Patients Who Failed Previous Therapy | Leukemia | phase-2 | Among the 10 patients, 1 achieved complete remission, 2 achieved CR with incomplete hematologic recovery, 1 achieved partial remission, and 2 had no remission, with 2 patients with MDS achieving marrow CR. | Source → |
| Combining Venetoclax with Chemotherapy for Acute Myeloid Leukemia | Leukemia | preclinical | Composite complete remission was achieved in 85.3% of patients. | Source → |
| New CLL Treatment Combination Shows Promise | Leukemia | phase-3 | These findings support fixed-duration regimens as a paradigm shift, optimizing efficacy, safety, and patient convenience in frontline CLL therapy. | Source → |
| New Treatment Combination Shows Promise for Rare Leukemia | Leukemia | phase-2 | — | Source → |
| Venetoclax Efficacy and Safety in CLL Patients | Leukemia | observational | — | Source → |
| New Treatment Combination Shows Promise for Relapsed Leukemia Patients | Leukemia | phase-1 | The overall response rate of treated patients was 42%. | Source → |
| New Treatment Combination Shows Promise for Leukemia Patients | Leukemia | phase-1 | The overall response rate was significantly higher in the CDCAG-VEN group than in the CDCAG-treated group (78.6% vs. 45.5%). | Source → |
| Venetoclax and Low-Intensity Chemotherapy for Acute Lymphoblastic Leukemia | Leukemia | preclinical | Among patients with newly diagnosed ALL, 10 of 11 (90.9%) achieved a measurable residual disease-negative complete remission. | Source → |
| Rare Cancer Treated with New Combination Therapy | Leukemia | observational | — | Source → |
| New Combination Therapy Shows Promise Against Resistant Leukemia Cells | Leukemia | lab-study | — | Source → |
| New Model Helps Predict Outcomes for Leukemia Patients | Leukemia | observational | Median overall survival (mOS) was 7.9 months. | Source → |
| Combining Medications May Improve Outcomes for Leukemia Patients | Leukemia | phase-3 | VAH significantly improved the rates of composite complete remission (44.3% vs. 66.3%), measurable residual disease negativity (34.8% vs. 59.3%), prolonged overall survival (median: 15.1 months vs. not reached), and event-free survival (median: 3.8 vs. 13.0 months). | Source → |
| New Treatment Options for High-Risk Acute Myeloid Leukemia | Leukemia | review | — | Source → |
| New Treatment Options for Patients with Unfit Acute Myeloid Leukemia | Leukemia | review | — | Source → |
| Venetoclax and Fluconazole Interaction in Leukaemia Patients | Leukemia | lab-study | — | Source → |
| Crushed Venetoclax Tablets May Not Work Well in Children with Leukemia | Leukemia | phase-1 | — | Source → |
| Venetoclax treatment for CLL linked to low risk of tumor lysis syndrome | Leukemia | observational | — | Source → |
| New Way to Predict Outcomes for AML Patients Treated with Venetoclax and Azacitidine | Leukemia | phase-3 | The new molecular signatures categorized patients into higher-, intermediate-, and lower-benefit groups, with median OS of 26.5 months, 12.1 months, and 5.5 months, respectively. | Source → |
| Combining Two Drugs May Help Treat Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combining Venetoclax and Azacitidine for Acute Myeloid Leukemia | Leukemia | observational | The composite complete remission achievement rate was 61.5%. | Source → |
| New Approach to Overcome Resistance to Leukemia Treatment | Leukemia | lab-study | — | Source → |
| Venetoclax Combination Therapy for Relapsed AML Shows Promise | Leukemia | meta-analysis | The pooled complete remission (CR) rate was 15.4%, and the composite complete remission (CRc) rate was 35.7%. | Source → |
| New Treatment Option for Rare Leukemia | Leukemia | preclinical | — | Source → |
| Combining Ruxolitinib with Other Medications May Help Treat Resistant Leukemia | Leukemia | preclinical | — | Source → |
| New Treatment Combination Shows Promise for Rare Cancer | Leukemia | phase-2 | — | Source → |
| Venetoclax Concentrations in Acute Leukemia Patients | Leukemia | lab-study | — | Source → |
| Venetoclax Shows Promise in Treating Pediatric Leukemia | Leukemia | observational | Most patients achieved early complete remission. | Source → |
| Combining Two Drugs Shows Promise in Treating Rare Leukemia | Leukemia | phase-1 | All patients achieved complete remission after only one cycle of treatment. | Source → |
| Venetoclax-based treatment for elderly leukemia patients | Leukemia | phase-2 | The composite response rate was 69% (CR = 50%, CRi = 4%, MLFS = 15%). | Source → |
| Comparing Treatments for Relapsed Leukemia | Leukemia | observational | Median OS was 6.8 months for the AZA-VEN group and 11.2 months for the NO-AZA-VEN group. | Source → |
| New Treatment Combination Shows Promise for CLL Patients | Leukemia | phase-2 | The estimated 3-year progression-free and overall survival rates were 85.0% and 93.8%, respectively. | Source → |
| Combining anlotinib and venetoclax may help treat acute myeloid leukemia | Leukemia | lab-study | — | Source → |
| New Treatment Combination Shows Promise for Acute Myeloid Leukemia | Leukemia | phase-3 | The VEN-HMA group achieved a significantly higher rate of complete remission (82.7%) compared to the HAG regimen (21.7%). | Source → |
| New Treatment Option for Resistant Leukemia | Leukemia | lab-study | — | Source → |
| Venetoclax treatment in CLL patients during COVID-19 pandemic | Leukemia | observational | The 30-day mortality rate was 4%. | Source → |
| New Treatment Options for Adult Leukemia Patients | Leukemia | phase-2 | — | Source → |
| Comparing Costs of CLL Treatments in Real-World Settings | Leukemia | observational | — | Source → |
| Venetoclax and Hypomethylating Agents in Acute Myeloid Leukemia Treatment | Leukemia | phase-2 | — | Source → |
| CLL Patients Retreated after Ibrutinib Plus Venetoclax May Avoid Resistance Mutations | Leukemia | phase-2 | — | Source → |
| Combining Medications May Improve CMML Treatment Outcomes | Leukemia | observational | The HMAs plus Vene group demonstrated superior overall response rates compared to the HMA mono group after four cycles (53.8% vs. 15.7%, p = 0.04). | Source → |
| New Treatment Combination Shows Promise for Rare Leukemia | Leukemia | lab-study | The patient achieved complete remission with venetoclax plus ATRA. | Source → |
| Targeting S100A9 Protein May Help Treat Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| Venetoclax Adherence Better Than BTKis in CLL Patients | Leukemia | observational | The venetoclax group had higher adherence (61.9%) and lower discontinuation (28.5%) compared to the BTKi group. | Source → |
| New Approach to Treating Acute Myeloid Leukemia | Leukemia | review | — | Source → |
| Combining Venetoclax and Azacitidine Treats Some Relapsed Acute Myeloid Leukemia Patients | Leukemia | phase-2 | 22.2% of patients in the group achieved complete remission or complete remission with incomplete blood count recovery. | Source → |
| New Treatment Approach for Aggressive Blood Cancer Shows Promise | Leukemia | observational | The 3 patients were evaluated as CR after allo-HSCT (+21 to +28 d) | Source → |
| ABCC1 protein limits effectiveness of leukemia treatment | Leukemia | lab-study | — | Source → |
| Venetoclax Dose Adjustments Due to Interactions with Other Medications | Leukemia | observational | — | Source → |
| Venetoclax May Be a Good Option for Unfit AML Patients | Leukemia | meta-analysis | Venetoclax plus azacitidine had a hazard ratio of 0.30 compared to enasidenib plus azacitidine, indicating improved survival. | Source → |
| Venetoclax and Hypomethylating Agents for Relapsed Leukemia | Leukemia | meta-analysis | The pooled complete response and complete response with incomplete blood count recovery rate was 32% (95% CI, 26-39%, I = 0%). | Source → |
| Combining FLAG-Ida and Venetoclax for Acute Myeloid Leukemia Treatment | Leukemia | review | Complete remission rates ranged between 53% and 78% for relapsed/refractory AML, and 89% for newly-diagnosed AML. | Source → |
| Combining Venetoclax with Other Medications to Treat Leukemia | Leukemia | observational | The overall response rate was 57.7%. | Source → |
| Venetoclax Treatment for Leukaemia: Outpatient Escalation Risks | Leukemia | observational | — | Source → |
| Venetoclax Effectiveness in Chronic Lymphocytic Leukemia | Leukemia | observational | — | Source → |
| Understanding CLL Resistance to Venetoclax | Leukemia | lab-study | — | Source → |
| Venetoclax and Hypomethylating Agents Improve Outcomes in Acute Myeloid Leukemia | Leukemia | observational | The complete remission rate was 44.1% in refractory patients and 39.7% in relapsed patients. | Source → |
| Old Patient with Rare Cancer Achieves Remission with New Treatment | Leukemia | observational | — | Source → |
| Venetoclax Efficacy for Chronic Lymphocytic Leukemia | Leukemia | review | — | Source → |
| Leukemia Treatment May Improve with RNA Splicing Modulation | Leukemia | lab-study | — | Source → |
| Venetoclax-based therapy for AML: Challenges and Future Directions | Leukemia | lab-study | — | Source → |
| Venetoclax Therapy May Help Some AML Patients After Other Treatments Fail | Leukemia | observational | The overall response rate was 56.8% and a median overall survival of 9.2 months. | Source → |
| Combining Drugs May Improve Leukemia Treatment | Leukemia | lab-study | — | Source → |
| New Treatment Option for Older Adults with Leukemia | Leukemia | phase-3 | Ven+Aza was associated with a gain of 1.65 quality-adjusted life years (QALYs) compared with Aza. | Source → |
| Venetoclax Shows Promise in Treating Acute Lymphoblastic Leukemia | Leukemia | review | — | Source → |
| Venetoclax-Rituximab Treatment Shows Long-Term Benefits in CLL Patients | Leukemia | phase-3 | Survival benefits with VenR vs BR were sustained (median PFS: 53.6 vs 17.0 months, respectively, P < .0001; 5-year OS: 82.1% vs 62.2%, P < .0001). | Source → |
| New Study Compares Outcomes for Leukemia Patients | Leukemia | phase-3 | — | Source → |
| Combining drugs may help treat acute myeloid leukemia | Leukemia | lab-study | — | Source → |
| Venetoclax Improves Leukaemia Treatment in Some Patients | Leukemia | phase-3 | The MRD-negative composite complete response rate was 86% in the venetoclax plus intensive chemotherapy cohort. | Source → |
| Venetoclax and Azacitidine or Decitabine Combination Therapy Risks in Acute Myeloid Leukemia | Leukemia | observational | — | Source → |
| Combining Cancer Drugs Enhances DNA Damage in Leukemia Cells | Leukemia | lab-study | — | Source → |
| Cost-Effective CLL Treatment Option Identified | Leukemia | phase-3 | — | Source → |
| Understanding How AML Patients Respond to Venetoclax-Based Treatments | Leukemia | review | — | Source → |
| Venetoclax Improves Outcomes for AML Patients | Leukemia | phase-3 | A 30% reduction in the risk of death with venetoclax, and median overall survival was 8.4 vs. 4.1 months. | Source → |
| Venetoclax Penetrates into Brain Fluid in Leukemia Patient | Leukemia | lab-study | — | Source → |
| New Treatments for Rare Blood Cancers | Leukemia | review | — | Source → |
| New Treatment Shows Promise for Relapsed Leukemia Patients | Leukemia | phase-3 | DEC10-VEN conferred significantly higher responses compared with IC including higher overall response rate (60% vs 36%) | Source → |
| Combining two drugs may improve treatment for acute myeloid leukemia | Leukemia | lab-study | The combinatory treatment presented lower IC values than single treatment of either venetoclax or embelin alone in both cell lines analyzed. | Source → |
| New Venetoclax-Based Therapies for Chronic Lymphocytic Leukemia | Leukemia | review | — | Source → |
| Effect of Azole Antifungals on Blood Cell Recovery in AML Patients | Leukemia | phase-2 | — | Source → |
| Combining Two Drugs to Fight Leukemia | Leukemia | lab-study | — | Source → |
| New Response Criteria Considered for Acute Myeloid Leukemia Treatment | Leukemia | phase-2 | — | Source → |
| New Cancer Treatment Combination Shows Promise for Older Adults | Leukemia | phase-2 | The 2-year disease-free survival rate was 75.0%. | Source → |
| Venetoclax Blood Levels Linked to Treatment Outcomes in Leukemia Patients | Leukemia | observational | Patients with venetoclax blood concentrations maintained within the range of 2605-4060 ng/mL achieved superior outcomes and higher safety profiles. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.